Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 15.05B +80.2% |
| Revenue (ttm) | 4.72B +13.5% |
| Net Income | 205.95M |
| EPS | 3.10 |
| Shares Out | 64.91M |
| PE Ratio | 74.81 |
| Forward PE | 8.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,343 |
| Open | 233.23 |
| Previous Close | 229.74 |
| Day's Range | 231.56 - 233.48 |
| 52-Week Range | 128.80 - 266.38 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 295.50 (+27.49%) |
| Earnings Date | Nov 2, 2026 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price target is $295.5, which is an increase of 27.49% from the latest price.
News
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Jefferies...
Jazz Pharmaceuticals price target raised to $305 from $296 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $305 from $296 and keeps an Outperform rating on the shares. The company delivered a…
Jazz Pharmaceuticals price target raised to $310 from $300 at JPMorgan
JPMorgan raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $310 from $300 and keeps an Overweight rating on the shares.
Jazz Pharmaceuticals price target raised to $319 from $314 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $319 from $314 and keeps an Overweight rating on the shares. The oxybate franchise is holding up better…
Jazz Pharmaceuticals price target raised to $275 from $271 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $275 from $271 and keeps an Overweight rating on the shares. The company’s Q3 performance shows…
Jazz Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue hit a record $1.24B, up 10% YoY, and FY 2026 revenue guidance rose to $4.775B-$4.85B. Ziihera launched in first-line GEA, while the Actio acquisition added ABS-1230 to the pipeline.
Jazz Pharmaceuticals Earnings release: Q3 2026
Jazz Pharmaceuticals released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Jazz Pharmaceuticals Quarterly report: Q3 2026
Jazz Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 2, 2026.
Jazz Pharmaceuticals Slides: Q3 2026
Jazz Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Jazz Pharmaceuticals reports Q3 non-GAAP EPS ($3.88), consensus ($2.38)
Reports Q3 revenue $1.24B, consensus $1.21B. “Our Q3 performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance,” said Renee Gal...
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) – – Company raises full year 2026 total revenue guidance – – Ziihera® launched in HER2+ 1L mGEA – – Xywav® reve...
Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026
Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare brain cancers For U.S. media and investors only DUBLIN, Nov. 2, 2026 /PRNewswire/ -- Jazz Pha...
Jazz Pharmaceuticals price target raised to $300 from $276 at JPMorgan
JPMorgan raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $300 from $276 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect…
Jazz announces updated overall survival results from HERIZON-GEA-01 trial
Jazz Pharmaceuticals (JAZZ) announced updated overall survival results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without Tevimbra, as first-lin...
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months Mature HERIZON-GEA-01 results show Ziihera...
Jazz Pharmaceuticals price target lowered to $314 from $322 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $314 from $322 and keeps an Overweight rating on the shares.
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026, after the close of th...
Jazz Pharmaceuticals price target raised to $313 from $307 at BofA
BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $313 from $307 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview…
Jazz Pharmaceuticals price target lowered to $296 from $299 at RBC Capital
RBC Capital lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $296 from $299 and keeps an Outperform rating on the shares as part of a broader research note…
Jazz Pharmaceuticals price target raised to $286 from $281 at Truist
Truist raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $286 from $281 and keeps a Buy rating on the shares as part of a broader research note previewing…
Jazz Pharmaceuticals initiated with a Buy at Citi
Citi initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating and $325 price target The firm believes the company’s oncology “transformation” is underappreciated at current share levels. Ci...
Jazz Pharmaceuticals resumed with a Buy at Goldman Sachs
Goldman Sachs resumed coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating and $337 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform...
Jazz Pharmaceuticals Transcript: Deutsche Bank 2026 Healthcare Summit
Zanidatamab continues to show strong efficacy in HER2-driven cancers, with expansion into new indications and a focus on triplet regimens. EPIDIOLEX’s label is set to broaden, and the pipeline is reinforced by targeted epilepsy and sleep disorder assets. Oncology and epilepsy will drive growth through 2030.
Jazz Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Oncology revenue grew 32% year-over-year, driven by new launches and strong zanidatamab data, with peak sales guidance raised to $3–$5 billion. The portfolio is diversified across oncology, sleep, and epilepsy, with robust financials, ongoing business development, and a focus on innovation and execution.
Jazz Pharmaceuticals completes acquisition of Actio Biosciences
Jazz Pharmaceuticals (JAZZ) announced the successful completion of its acquisition of privately-held Actio Biosciences for $820M upfront. Actio is now a wholly-owned subsidiary of Jazz.